Trial document





This trial has been registered retrospectively.
drksid header

  DRKS00017414

Trial Description

start of 1:1-Block title

Title

Long term efficacy and safety of tenofovir alafenamide fumarate (TAF) in patients with chronic hepatitis B virus(HBV) infections: an observational, non-interventional trial (TOUGH trial)

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

TOUGH

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Observation of safety and efficacy of tenofovir alafenamide fumarat (TAF) in patients with Hepatitis B mono-infection

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

The nucleotide analogue (NA) tenofovir disoproxil fumarate (TDF) has become a mainstay in the treatment of chronic hepatitis B virus (HBV) infections worldwide. TDF is characterized by both high antiviral potency and high genetic barrier against resistance development with high antiviral activity against wild type or HBV variants associated with resistance.To date no confirmed genotypic HBV resistance mutation against TDF in CHB has been reported. Although generally well tolerated, treatment with TDF has rarely been associated with a decline of glomerular filtration rate. In addition, decrease of mineral bone density has been reported. Discontinuation of the drug may improve kidney function but sequelae may remain. Tenofovir alafenamide fumarate (TAF) is also a prodrug of tenofovir which has been licensed for chronic hepatitis B in Germany since 09.01.2017. The use of TAF allows lower dosages as TDF achieving the same level of antiviral potency. In phase 3 clinical trials of TAF, no inferiority to TDF could be established with lower incidence of side effects, especially nephrotoxicity and mineral bone density. In vitro studies have shown that TAF also exerts antiviral potency against HBV variants associated with resistance development. Current experince of treatment with TAF in chronic hepatitis B infection derives from randomized clinical trials. Focus of these trials were were efficacy and safety measured by virological and biochemical markers, which monitor potential side effects associated with tenofovir such as nephrotoxicity, decline of mineral bone density and elevation of lipid panel.
The current European guideline (EASL 2017. Clinical Practice Guidelines on the management of hepatitis B virus infection) recommends the monitoring of liver function and inflammation, renal function and mineral bone density before initiating treatment and during administration of TAF.
The currrent drug information of TAF recommends regular surveillance of hepatotoxicity und nephrotoxicity, monitoring of ALT-levels (Fachinformation Vemlidy 2017).
Since most patients do not qualify for clinical trials, safety and efficacy of TAF needs to be evaluated in a real-world setting.
The aim of our prospective non interventional trial ist to evalaute the efficacy and safety in patients who receive treatment with TAF to the discretion of their physician.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00017414
  •   2019/09/25
  •   [---]*
  •   yes
  •   Approved
  •   294/17-ek, Ethikkommission an der Medizinischen Fakultät der Universität Leipzig
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   B18.1 -  Chronic viral hepatitis B without delta-agent
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Patients receiving treatment with tenofovir alafenamide fumarat (TAF) are monitored for antiviral efficacy and safety for the duration of 3 years. In accordance with international guidelines and the current drug information regular surveillance of laboratory markers and side effects is carried out.
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Observational study
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Treatment
  •   Single (group)
  •   N/A
  •   No
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Percentage of patients achieving undetectable levels of HBV DNA after 6, 12, 24 and 36 months of treatment with TAF
- Percentage of patients achieving HBsAg loss during treatment with TAF
- Percentage of patients achieving HBeAg seroconversion treatment with TAF
- Percentage of patients developing a decrease in renal function during treatment

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- side effects during treatment with TAF
- Changes in HBsAg levels during TAF treatment
- Percentage of patients with virologic failure defined as:
- Confirmed re-increase in HBV DNA levels > 1 log after initial response to TAF
- Absence of decrease of HBV DNA > 1 log wihin 12 month of TAF treatment -
Partial response: HBV DNA levels > 400 copies/mL after 1, 2 and 3 years of TAF treatment
- changes of ALT levels during tough treatment
- changes of renal function during treatment
- Changes in mineral bone density and lipid panel if diagnostic test are carried out to the disretion of the current physician
- changes of liver stiffness during treatment if available
- Changes in the HBV polymerase gene in patients with virologic failure to TAF treatment - Change in liver stiffness during TAF treatment

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • Medical Center 
  • Doctor's Practice 
  • Doctor's Practice 
  • Doctor's Practice 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2018/10/01
  •   200
  •   Multicenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

1. Chronic HBV infection diagnosed at least 6 months prior to inclusion in trial (HBsAg positive > 6 months)
2. Patients receiving newly initiated treatment with TAF or
3. Treatment experienced patients who switch from ongoing antiviral treatment to TAF
3. Age ≥ 18 years
4. Signed informed consent form

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

1. Patients who are not willing or able to sign informed consent.
2. Patients with HBV/HIV or HBV/HCV or HBV/HDV coinfection

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Universitätsklinikum Leipzig
    • Liebigstr. 18
    • 04103  Leipzig
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Klinik für Gastroenterologie, Universitätsklinikum Leipzig
    • Mr.  PD Dr. med.  Florian  van Bömmel 
    • Liebigstr. 20
    • 04103  Leipzig
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Klinik für Gastroenterologie, Universitätsklinikum Leipzig
    • Ms.  Claudia  Breithaupt 
    • Liebigstr. 20
    • 04103  Leipzig
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Gilead Sciences
    • 333 Lakeside Drive
    • 94404  Foster City
    • United States
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.